Advertisement
Advertisement

ACAD

ACAD logo

Acadia Pharmaceuticals Inc.

26.98
USD
Sponsored
+0.83
+3.15%
Jan 06, 15:58 UTC -5
Closed
exchange

After-Market

26.71

-0.26
-0.96%

ACAD Earnings Reports

Positive Surprise Ratio

ACAD beat 26 of 40 last estimates.

65%

Next Report

Date of Next Report
Feb 24, 2026
Estimate for Q4 25 (Revenue/ EPS)
$299.10M
/
$0.14
Implied change from Q3 25 (Revenue/ EPS)
+7.35%
/
-66.67%
Implied change from Q4 24 (Revenue/ EPS)
+15.22%
/
-800.00%

Acadia Pharmaceuticals Inc. earnings per share and revenue

On Nov 05, 2025, ACAD reported earnings of 0.42 USD per share (EPS) for Q3 25, beating the estimate of 0.15 USD, resulting in a 178.15% surprise. Revenue reached 278.63 million, compared to an expected 282.00 million, with a -1.19% difference. The market reacted with a -3.05% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 22 analysts forecast an EPS of 0.14 USD, with revenue projected to reach 299.10 million USD, implying an decrease of -66.67% EPS, and increase of 7.35% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
Dec 23, 2025 For Q4 25
Estimate
-$0.12
Actual
-$0.06
Surprise
+50.98%
FAQ
For Q3 2025, Acadia Pharmaceuticals Inc. reported EPS of $0.42, beating estimates by 178.15%, and revenue of $278.63M, -1.19% below expectations.
The stock price moved down -3.05%, changed from $22.33 before the earnings release to $21.65 the day after.
The next earning report is scheduled for Feb 24, 2026.
Based on 22 analysts, Acadia Pharmaceuticals Inc. is expected to report EPS of $0.14 and revenue of $299.10M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement